<!DOCTYPE html>
<html lang="en-US">

<head>
<!-- https://www.ncbi.nlm.nih.gov/projects/msaviewer/ -->
<!-- This viewer will expire in 1-2 months. Update or embed our own -->


<!-- <script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/projects/msaviewer/js/multialign.js"></script></head> -->


  <script async src="https://www.googletagmanager.com/gtag/js?id=UA-199638391-1"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());
    gtag('config', 'UA-199638391-1');
  </script>

<meta charset="UTF-8">

	<title>
        SARS-CoV-2 variants
    </title>


<!-- Begin Jekyll SEO tag v2.7.1 -->
<title>AZD2816 | SARS-CoV-2 variants</title>
<meta name="generator" content="Jekyll v3.9.0" />
<meta property="og:title" content="AZD2816" />
<meta property="og:locale" content="en_US" />
<meta name="description" content="Open-source tracking for emerging SARS-CoV-2 variants that pose a risk based on COVID-19 vaccine genetics." />
<meta property="og:description" content="Open-source tracking for emerging SARS-CoV-2 variants that pose a risk based on COVID-19 vaccine genetics." />
<link rel="canonical" href="http://localhost:4000/data/source_notes/AZD2816/AZD2816.html" />
<meta property="og:url" content="http://localhost:4000/data/source_notes/AZD2816/AZD2816.html" />
<meta property="og:site_name" content="SARS-CoV-2 variants" />
<meta name="twitter:card" content="summary" />
<meta property="twitter:title" content="AZD2816" />
<script type="application/ld+json">
{"description":"Open-source tracking for emerging SARS-CoV-2 variants that pose a risk based on COVID-19 vaccine genetics.","url":"http://localhost:4000/data/source_notes/AZD2816/AZD2816.html","headline":"AZD2816","@type":"WebPage","@context":"https://schema.org"}</script>
<!-- End Jekyll SEO tag -->

<link rel="preconnect" href="https://fonts.gstatic.com">
<link rel="preload" href="https://fonts.googleapis.com/css?family=Open+Sans:400,700&display=swap" as="style" type="text/css" crossorigin>
<meta name="viewport" content="width=device-width, initial-scale=1">
<meta name="theme-color" content="#157878">
<meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
<link rel="stylesheet" href="/assets/css/style.css?v=90f78b06d3ba2b6eadfc5a2dd32091c682528112">
</head>

<body>
<!-- <a id="skip-to-content" href="#content">Skip to the content.</a> -->
<header class="page-header" role="banner">

<div class="particle-1"></div>
<div class="particle-2"></div>
<div class="particle-3"></div>
<div class="particle-4"></div>

<div class="project-name" >
	<h1> SARS-CoV-2 variants </h1>
  <h2 class="project-tagline">Open-source tracking for emerging SARS-CoV-2 variants that pose a risk based on COVID-19 vaccine genetics.</h2>
  

</div>  
</header>

<!-- MSA viewer -->
<div id="msaviewer_x6f6y" class="MultiAlignViewerApp" data-autoload>
<a href="?embedded=true&anchor=-1&coloring=fbd&key=qhkwwLYbacLFNSfF5iQRO0GVWVAGIQgkBCIsNDgwKh67Eg5CyHhYWzczAoYJoxPeQsYf0gH2WvMd6QnkD-ID-THQDN4g4go,jT4X55E8TuXiEgDiwQM2HGayfnYhBy8CIwQLEh8WDTicNClk714CS8TL8QFrLrlT6Eu1X6t78H63ZKNppW-pdJtdplOKb6A&track_config=protein_default&from=207&to=278&columns=d:120,b:55,x:17,aln,e:55,o:150&appname=ncbi_msav_demo"></a>
</div>

	<!-- <div id="7db9ZE" class="SeqViewerApp" data-autoload> -->
<!-- <a href="?embedded=true&url=https://raw.githubusercontent.com/DylanLawless/SARS-CoV-2-VOC.github.io/main/UCSCGenes_exon20.bed&appname=MyCompany_MyApp"></a> -->
<!-- </div> -->

    <main id="content" class="main-content" role="main">
      <h2 id="azd2816">AZD2816</h2>
<blockquote>
  <p>AZD2816 has been built using the same adenoviral vector platform as with Vaxzevria, with minor genetic alterations to the spike protein based on the Beta (B.1.351, South African) variant. 
The Beta variant vaccine contains ten changes across the spike protein, many of which are also seen in other variants of concern, and which lead to effects such as, 
reduced ability of antibodies induced against the original virus to block cell entry (K417N, E484K, N501Y); 
increased infectivity compared to the original virus (D614G); reduced sensitivity of neutralising antibodies to the original virus (L452R). 
These modifications are only minor and in all other ways the two vaccines are the same.</p>
</blockquote>

<p><a href="https://www.astrazeneca.com/media-centre/press-releases/2021/first-covid-19-variant-vaccine-azd2816-phase-ii-iii-trial-participants-vaccinated.html">https://www.astrazeneca.com/media-centre/press-releases/2021/first-covid-19-variant-vaccine-azd2816-phase-ii-iii-trial-participants-vaccinated.html</a></p>

<p>Pre-print indicating the genetics of this vaccine sequence.Although only 9 variants compared to reference are reported - presumably the press-release counts the 242-243del as two.</p>

<p><a href="https://www.biorxiv.org/content/biorxiv/early/2021/06/09/2021.06.08.447308.full.pdf">https://www.biorxiv.org/content/biorxiv/early/2021/06/09/2021.06.08.447308.full.pdf</a></p>

<blockquote>
  <p>In this study we describe the generation and preclinical assessment of ChAdOx1 expressing B.1.351 spike protein; AZD2816.</p>
</blockquote>

<p>Fig 1 of this preprint shows “ Amino acid changes between original and B.1.351 variant virus and encoded in the AZD2816 vaccine”:</p>

<ul>
  <li>L18F</li>
  <li>D80A</li>
  <li>D215G</li>
  <li>242-243del</li>
  <li>K417N</li>
  <li>E484K</li>
  <li>N501Y</li>
  <li>D614G</li>
  <li>A701V</li>
</ul>

<blockquote>
  <p>AZD2816 modified YP_009724390.1 variants from B.1.351
MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTL–LHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT</p>
</blockquote>

<blockquote>
  <p>AZD2816 modified YP_009724390.1 variants from B.1.351
—————–F————————————————————-A————————————————————————————————————————————–G————————–XX—————————————————————————————————————————————————————————–N——————————————————————K—————-Y—————————————————————————————————————-G————————————————————————————–V——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————-</p>
</blockquote>



	<footer class="site-footer">
		
		<span class="site-footer-owner">
		<a href="https://lawlessgenomics.com"><img src="/images/logos/logo4.2_150ppi.png" 
		alt="Logo image" width="17.85" height="27.25" /></a>
		<a href="https://github.com/DylanLawless/SARS-CoV-2-VOC.github.io">SARS-CoV-2-VOC.github.io</a> is maintained by <a href="https://github.com/DylanLawless">DylanLawless</a>
		</span>
		
	<!-- <span class="site-footer-credits">This page was generated by <a href="https://pages.github.com">GitHub Pages</a>.</span> -->
	<form action="https://www.paypal.com/donate" method="post" target="_top">
<input type="hidden" name="hosted_button_id" value="UU3F4ND2JAP2W" />
<input type="image" src="https://www.paypalobjects.com/en_US/i/btn/btn_donate_SM.gif" border="0" name="submit" title="PayPal - The safer, easier way to pay online!" alt="Donate with PayPal button" />
<img alt="" border="0" src="https://www.paypal.com/en_IE/i/scr/pixel.gif" width="1" height="1" />
</form>
	<!--- https://www.paypal.com/donate?hosted_button_id=UU3F4ND2JAP2W --->
	</footer>
    </main>
  </body>
</html>
